Advanced

Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.

Tanner, MM; Isola, JJ; Wiklund, T; Erikstein, B; Kellokumpu-Lehtinen, P; Malmström, Per LU ; Wilking, N; Nilsson, J and Bergh, J (2005) 2005 ASCO Annual Meeting In Journal of Clinical Oncology 23(16S). p.841-841
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Clinical Oncology
volume
23
issue
16S
pages
841 - 841
publisher
American Society of Clinical Oncology
conference name
2005 ASCO Annual Meeting
external identifiers
  • wos:000230326605403
ISSN
1527-7755
language
English
LU publication?
yes
id
d82ab9cb-2c82-482b-adf2-93ef72567e1e (old id 226787)
alternative location
http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/9518
date added to LUP
2009-07-13 13:25:56
date last changed
2016-04-15 20:23:49
@misc{d82ab9cb-2c82-482b-adf2-93ef72567e1e,
  author       = {Tanner, MM and Isola, JJ and Wiklund, T and Erikstein, B and Kellokumpu-Lehtinen, P and Malmström, Per and Wilking, N and Nilsson, J and Bergh, J},
  issn         = {1527-7755},
  language     = {eng},
  note         = {Conference Abstract},
  number       = {16S},
  pages        = {841--841},
  publisher    = {American Society of Clinical Oncology},
  series       = {Journal of Clinical Oncology},
  title        = {Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.},
  volume       = {23},
  year         = {2005},
}